

3,5-diiodothyronine: a novel thyroid hormone metabolite and potent modulator of e...

[Health & Medicine](#)



Introduction

Thyroid hormones [3, 5, 3', 5'-tetraiodo-L-thyronine (T4) and 3, 5, 3'-triiodothyronine (T3), THs] play critical roles in differentiation, growth, and metabolism ([1](#), [2](#)). THs act via the nuclear thyroid hormone receptors (THRs), through different modes of action which, accordingly with Flamant ([3](#)), can be classified as: THR-dependent signaling of TH with direct binding to DNA; THR-dependent signaling of TH with indirect binding to DNA and THR-dependent signaling of TH without DNA binding; however, also THR-independent TH signaling is involved in TH mode of action ([4](#)). The different modes of action may be coupled, and several reports have recently shown that several TH metabolites act accordingly ([5](#) - [8](#)).

3, 5-diiodo-L-thyronine (3, 5-T2) has emerged as a biologically active iodothyronine ([9](#) - [11](#)). Mitochondria and bioenergetic mechanisms seem to be major targets of 3, 5-T2. Here, we review the most recent findings on the peripheral actions of 3, 5-T2 and discuss the possible role of 3, 5-T2 in the modulation of thyroid-related effects in organisms ranging from non-mammals to humans.

The Rapid Effects of 3, 5-T2 on Energy Metabolism

At 1 pM concentration, 3, 5-T2 stimulates oxygen consumption more rapidly than T3 in perfused hypothyroid rat liver ([12](#)). Acute administration of T3 and 3, 5-T2 to rat enhances mitochondrial activities ([13](#), [14](#)), with 3, 5-T2 producing more rapid events (within 1 h) than T3 (after 24 h) and cycloheximide-independent ([15](#)).

The rapid increase in mitochondrial oxygen consumption by 3, 5-T₂ is reflected at the whole animal level ([16](#)). Injecting a single dose of 3, 5-T₂ (25 µg/100 g BW) to rats simultaneously administered with propylthiouracil (P) and iopanoic acid (I) (referred to as P+I, which results in severe hypothyroidism and inhibition of all the deiodinase activities) results in an increased resting metabolic rate (RMR) which is more rapid (within 6 h) than that induced by T₃ (15 µg/100 g BW, effect seen within 25 h) ([17](#)). The effects following T₃ injection in this study were like those reported by Tata ([18](#)), who injected the same dose. Simultaneous injection of Actinomycin D blocked the effects of T₃ but not of 3, 5-T₂ ([17](#)), thus excluding the involvement of transcription in the effects of 3, 5-T₂. Indeed, it has been shown that the affinity of 3, 5-T₂ for human THRβ is 60-fold lower compared to T₃ ([19](#)). Moreover, when injected into euthyroid rats, the effect of T₃ on RMR is evident 25 h earlier than in P+I animals and is independent of Actinomycin D, suggesting that the effect of T₃ injection could be due, at least in part, to the *in vivo* formation of 3, 5-T₂ from T₃ as supported by its inhibition by P+I treatment and by the increased 3, 5-T₂ serum and liver levels following T₃ injection into euthyroid rats ([20](#)).

The addition of nanomolar concentrations of 3, 5-T₂ significantly increases cytochrome oxidase (COX) activity ([21](#)) as demonstrated by specific binding of radioactive 3, 5-T₂ to subunit Va, and by complete reversal of its effect on respiration by a monoclonal antibody to this subunit ([22](#), [23](#)). The addition of 3, 5-T₂ to a liposome-reconstituted COX complex results in partial uncoupling which could explain its *in vivo* thermogenic effect ([24](#)). Binding sites detected by photoaffinity labeling in the rat liver cytosol ([25](#)) and by

radioligand binding and displacement experiments in rat liver mitochondria ([22](#)) and cell membrane [shown by the *in vitro* activation of the Na^+/H^+ exchanger ([26](#))] support the involvement of these organelles in the rapid action of 3, 5-T₂ ([10](#), [26](#) - [29](#)). The 3, 5-T₂ mitochondrial binding was maximal at pH 7.0 and the values for the apparent association constant and the binding capacity were $0.5 \pm 0.04 \times 10^8 \text{ M}^{-1}$ and $0.4 \pm 0.04 \text{ pmol/mg}$ mitochondrial protein respectively ([21](#) - [23](#), [30](#)). A top-down elasticity analysis shows that 3, 5-T₂ (within 1 h from injection into euthyroid rats) stimulates hepatic activity of both cytochrome c-oxidizing and -reducing components of the respiratory chain ([31](#)). 3, 5-T₂ also rapidly stimulates skeletal muscle mitochondrial activity and uncoupling ([32](#), [33](#)). 3, 5-T₂ rapidly increases mitochondrial Ca^{2+} uptake through which the iodothyronine could increase mitochondrial activity and respiration ([34](#)). More recently, the rapid effects of 3, 5-T₂ on intracellular Ca^{2+} and NO through plasma membrane and mitochondrial pathways in pituitary GH3 cells ([35](#)) further support mitochondria as a principal target of 3, 5-T₂ effects.

Moreover, 3, 5-T₂ has direct and rapid effects (within 1 h) on mitochondrial F₁F₀-ATP synthase activity in the liver of hypothyroid rats ([36](#)), increases mitochondrial respiration rates, increases mitochondrial uncoupling and reduces H_2O_2 production ([37](#)).

The Effects of Long-Term Administration of 3, 5-T2 on Energy Metabolism

Chronic administration of 3, 5-T2 into P+I cold-exposed rats increases the energy capacity of the heart, skeletal muscle, liver, and brown adipose tissue (BAT), improving their survival in the cold ([38](#)).

Chronic administration of 3, 5-T2 into P+I rats induces significant stimulation of lipid β -oxidation ([39](#)), and upregulates rat-liver mitochondrial F(o)F(1)-ATP synthase by GA-binding protein/nuclear respiratory factor-2, thus providing new insights into the 3, 5-T2 role on bioenergetic mechanisms ([40](#)).

When injected into P+I rat, 3, 5-T2 increases skeletal muscle lipid handling through FAT/CD36 and mitochondrial oxidation ([41](#)), activates thermogenesis, with UCP1 likely acting as the molecular determinant of this effect, and increases the sympathetic innervation and vascularization of BAT ([42](#)).

The Hypolipidemic Effects of 3, 5-T2

The effects of 3, 5-T2 on energy metabolism has prompted research *in vitro* and *in vivo* on whether and how 3, 5-T2 administration could improve adiposity and associated disorders.

***In Vitro* Studies**

Primary rat hepatocytes exposed to the classical oleate/palmitate (2: 1 ratio) mixture have been employed as *in vitro* model of “ fatty hepatocytes” to assess the effects of 3, 5-T2 and T3 (doses of 10^{-7} or 10^{-5} M for 24 h) on

lipid metabolism ([43](#)). 3, 5-T2 and T3 reduce the number and average sizes of lipid droplets, thus making stored triglycerides (TGs) more accessible to enzymes acting on the catabolism/secretion of free fatty acids. More recently, 3, 5-T2 has been shown to reduce lipid excess in fatty hepatocytes by recruiting triglyceride lipase on the lipid droplet surface ([44](#)). 3, 5-T2 also reduces lipid content and triggers phosphorylation of Akt in an insulin receptor-independent manner when incubated with NAFLD-like rat primary hepatocytes ([45](#)). Furthermore, 3, 5-T2 enhances glucose-induced insulin secretion in both rat β -cells and human islets ([46](#)).

When exposed to an oleate/palmitate (2: 1 ratio) mixture and treated with 3, 5-T2 or T3 (doses of 10^{-7} or 10^{-5} M for 24 h), FAO rat hepatoma cell lines, defective for functional THRs, show reduced TGs content, reduced number and size of lipid droplets and stimulated mitochondrial uncoupling ([47](#)), supporting a THR-independent TH signaling mechanisms which involve both 3, 5-T2 and T3 through stimulation of mitochondrial uncoupled respiratory activity ([47](#)).

In HepG2 cells, 3, 5-T2 blocks the proteolytic cleavage of SREBP-1 without affecting its expression, thus reducing fatty acid synthase expression in a way dependent on the concurrent activation of MAPK, ERK, and p38 and Akt and PKC- δ pathways ([48](#)).

***In Vivo* Studies**

Hypolipidemic effects have been studied *in vivo* by using several animal models ([49](#)). Simultaneous 3, 5-T2 (25 μ g/100 g BW) administration for 4 weeks to rats feeding a high-fat diet (HFD) prevents fatty liver and increases <https://assignbuster.com/35-diiodothyronine-a-novel-thyroid-hormone-metabolite-and-potent-modulator-of-energy-metabolism/>

in body weight by increasing fatty acid oxidation rate and mitochondrial uncoupling to burn fat ([50](#)). Reductions in serum TGs and cholesterol levels ([50](#)), as well as improved insulin sensitivity ([51](#)), are also associated with 3, 5-T2 administration. 3, 5-T2 elicits the deacetylation of hepatic peroxisome proliferator-activated receptor gamma coactivator 1-alpha and sterol regulatory element binding protein-1c (SREBP-1c) through direct induction of silent mating type information regulation 2 homolog 1 (SIRT1) activity, resulting in increased fatty acid oxidation and decreased lipogenesis, respectively ([51](#)). Though both 3, 5-T2 and T3 decrease the expression of hepatic SREBP-1c, 3, 5-T2 (administered at a daily dose of 25 µg/100 g BW to high-fat diet- fed rats for 1 week), in contrast to T3 (administered at a 10-fold lower dose), does not directly induce the expression of the TRE-containing SREBP-1c lipogenic target genes [acetyl-CoA carboxylase and fatty acid synthase ([52](#))]. This, at least in part, explains the effectiveness of 3, 5-T2 in preventing hepatic fat accumulation and insulin resistance. Iannucci ([53](#)) showed that both 3, 5-T2 and T3 exert lipolytic effects in the liver mediated by autophagy and increased fatty acid oxidation although the metabolic profiles suggested that there may be some differences in the mechanism(s) and magnitude of their metabolic effects. 3, 5-T2 ameliorates muscle glucose uptake by increasing the response to insulin of Akt/PKB phosphorylation and induces structural and biochemical shifts toward glycolytic myofibers ([54](#)), thus enhancing muscle glycolytic capacity producing metabolic benefits ([55](#) - [57](#)), reminiscent of those induced by resistance exercise ([58](#)). Mitochondria adapt to the glycolytic phenotype of gastrocnemius muscle both in terms of metabolism and of

dynamic with 3, 5-T2 being able in reverting the HDF-associated expression pattern of proinflammatory factors ([59](#)). At the doses of 25 µg 3, 5-T2/100 g BW for 4 weeks no signs of suppression of the hypothalamus-pituitary-thyroid (HPT) axis and cardiac hypertrophy are detected.

In streptozotocin-treated rats, 3, 5-T2 (at the dose of 25 µg/100 g BW for 12 weeks) protects against renal damage in diabetic nephropathy through SIRT1-dependent deacetylation and inactivation of subunit p65 of NF-κB, thus inhibiting the inflammatory process related to this disease ([60](#)). Ball in rats ([61](#)), reported that 3, 5-T2 is more effective in inducing hepatic malic enzyme gene expression than suppressing circulating TSH, indicating that tissue- and gene-selective effects of 3, 5-T2 are not only related to differences in binding of this thyromimetic ligand to various TR isoforms but also to distinct local cellular ligand availability.

3, 5-T2 administration to HFD-obese Wistar rats was also shown to reduce pre-existing hepatic fat accumulation through increased mitochondrial fatty acid oxidation coupled with less efficient utilization of substrates and reduced oxidative stress ([62](#)). A proteomic study showed that 3, 5-T2 counteracts several HFD-induced changes in the protein profile, mostly in the mitochondria ([63](#)). Moreover, blue native-PAGE (BN-PAGE)/in-gel activity analysis revealed that 3, 5-T2 treatment results in stimulation (vs. HFD) of respiratory complexes, thus explaining, at least in part, the anti-steatosis effect of 3, 5-T2. Administration of 3, 5-T2 [subcutaneously injected at doses of 25, 50, or 75 µg/100 g BW for 90 days] to chow-fed rats aged 3–6 months significantly reduces body mass and improves glucose tolerance, while heart

rate and mass remain unchanged, TSH levels remain normal in rats receiving 25 µg of 3, 5-T₂ /100 g BW but are slightly lowered in rats that received 50 and 75 µg of 3, 5-T₂ /100 g BW ([64](#)). In apparent contrast, 3, 5-T₂ administration to Sprague Dawley rats fed a safflower-oil based HFD fails to improve NAFLD or insulin sensitivity ([65](#)). One reason for this discrepancy may be that an unsaturated fat-predominant plant oil-based diet is used ([65](#)) that could mask the hypolipidemic effects of 3, 5-T₂ with saturated fat-predominant animal fat-based diets ([50](#), [51](#), [54](#), [62](#)). Furthermore, Sprague Dawley and Wistar rats display differences in both lipoprotein metabolism and endocrine function ([66](#)).

In diet-induced obese mice, daily administration of 3, 5-T₂ (250 µg/100g BW for 14 or 28 days i. p.) shows beneficial effects on adiposity, serum leptin, and energy expenditure ([67](#)). The lower dose of 3, 5-T₂ suppresses βTSH transcripts, thus suggesting a risk of interference of 3, 5-T₂ on the HPT axis as well as on the heart ([67](#)). Lean and diet-induced obese male mice treated for 4 weeks with a 3, 5-T₂ dose of 2.5 µg/g BW, show an altered expression of genes encoding hepatic xenobiotic-metabolizing enzymes involved in catabolism and inactivation of xenobiotics and TH as well as in hepatic steroid and lipid metabolism ([68](#)). Hence, the administration of this high dose of 3, 5-T₂ might exert adverse hepatic effects.

3, 5-T₂ (1.25 mg/100 g BW via daily gavage) reduces circulating total and LDL cholesterol as well as the liver level of apoB and circulating levels of both apoB48 and apoB100, but, at the same time, reduces plasma T₄ levels in Western type diet fed low-density lipoprotein receptor knockout mice ([69](#)).

). Both 3, 5-T₂ and T₃ administration significantly reduce nuclear HNF4 α protein content, while 3, 5-T₂, but not T₃, decreases the expression levels of the HNF4 α transcriptional coactivator PGC-1 α . Lower PPAR α levels are found only following T₃ treatment while both T₃ and 3, 5-T₂ lower liver X receptor α nuclear content ([70](#)). 3, 5-T₂ (1. 25 mg/100 g BW) decreases body weight and blood glucose levels through reductions in GLUT2 levels and changes in hepatic glucose output in obese mice showing to produce signs of thyrotoxicosis ([71](#)). Taken together, these studies suggest the possibility that the “ thyrotoxic effects” of 3, 5-T₂ may be dependent upon possible differences between experiments in rats vs. mice, normal weight vs. obese, or euthyroid vs. hypothyroid animals, age, diet and temperature of exposure. It is important to note, however, that 3, 5-T₂ did not suppress TSH as strongly as T₃ and that the cardiac readouts may represent an adaptation to increased metabolic rate, perhaps implying potential for separation of desirable effects from thyrotoxic effects.

At the current stage, no validated technique is available to accurately measure intracellular levels of 3, 5-T₂. Resolving this issue will bring to light to what extent 3, 5-T₂ is taken up in the tissues and how this relates to the effects of the exogenous administrations described above.

The Physiological and Pathophysiological Roles of 3, 5-T₂ in Humans

A case report ([72](#)) involving two participants revealed that administration of 3, 5-T₂ to humans (1–5 μ g/kg BW) rapidly (after 4–6 h) increased RMR.

Chronic 3, 5-T₂ administration (28 days, approximately 5 μ g/kg BW)

increases RMR by approximately 15% and decreases body weight by
<https://assignbuster.com/35-diiodothyronine-a-novel-thyroid-hormone-metabolite-and-potent-modulator-of-energy-metabolism/>

approximately 4 kg in both participants. Principal clinical parameters show no significant changes and no side effects (i. e., cardiac abnormalities) are observed.

As mentioned above, reliable quantification methods to measure endogenous levels of 3, 5-T2 have been lacking ([73](#) - [75](#)) and the data reported so far need independent analytical confirmation.

Recently, a mouse monoclonal antibody based on a new competitive chemiluminescence immunoassay was developed ([76](#)) to investigate the origin and action of 3, 5-T2 in humans under several conditions. Data by Pietzner ([77](#)) in euthyroid human serum point toward a physiological link between 3, 5-T2 (with a concentration of 0. 22-0. 33 nM) and glucose metabolism as well as TH homeostasis. Pietzner ([78](#)) screened the urine metabolome for associations with serum 3, 5-T2 concentrations in healthy individuals, resulting in a median serum concentration of 0. 24 nM. The detected metabolites are related to glucose and lipid metabolism, as well as the response to oxidative stress or drug metabolism, and are in concordance with previously published rat liver proteome analyses ([63](#)). Dietrich ([79](#)) reported elevated concentrations of 3, 5-T2 ($0. 59 \pm 0. 07$ nM vs. $0. 39 \pm 0. 04$) in cardiac Nonthyroidal Illness Syndrome (NTIS) suggesting that 3, 5-T2 elevations in NTIS could explain why patients with low-T3 syndrome substituted with T4/T3 do not benefit from exogenous TH administration. Langouche ([80](#)), in critically ill patients reported a 30% higher serum 3, 5-T2 concentration than healthy volunteers which are not independently correlated with TH.

Although recent studies in human gave some indications on the physiological and pathophysiological roles of 3, 5-T₂ in humans, further analyses on larger samples of euthyroid individuals are needed to obtain a more comprehensive picture of the role of 3, 5-T₂ in humans.

The Effects of 3, 5-T₂ in Non-mammalian Species

The effects of 3, 5-T₂ on metabolic efficiency is conserved across species. 3, 5-T₂ rapidly stimulates pyruvate-fuelled mitochondrial respiration of liver and muscle from goldfish *Carassius auratus* ([81](#)). After 12 or 24 h, 3, 5-T₂ rapidly decreases type 2 deiodinase (D2) activity in the liver of killifish, whilst not affecting type 1 deiodinase (D1) activity; moreover, after a 24 h exposure, 3, 5-T₂ (like T₄ and T₃) inhibits both D1 and D2 transcription ([82](#)). 3, 5-T₂ also regulates thermal acclimation in *Danio rerio* ([83](#)) and growth in tilapia ([84](#)). 3, 5-T₂ binds to and activates a specific long TR β 1 isoform that contains a nine-aminoacid insert at the beginning of the ligand-binding domain, whereas T₃ can interact also with a different TR β 1 isoform that lacks this insert ([19](#)). Hernández-Puga reported that 3, 5-T₂ represses THR β expression and impairs its up-regulation by cortisol possibly through a transrepression mechanism ([85](#)). Very recently, Olvera ([86](#)) reported that in tilapia cerebellum 3, 5-T₂ specifically regulates gene sets involved in cell signaling and transcriptional pathways, while T₃ regulated pathways related to cell signaling, immune system, and lipid metabolism.

Conclusions

Thirty years of research using mammalian and non-mammalian *in vivo* and *in vitro* models has generated substantial data on the biological effects of 3,

5-T2. However, a debate is open concerning the side-effects of 3, 5-T2, an issue that needs to be investigated by performing more comprehensive studies in humans and animal models to fully evaluate any potential risks.

Author Contributions

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

Funding

This research was financially supported by a grant from the University of Campania Luigi Vanvitelli and by a FAR grant from University of Sannio.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. *Physiol Rev.* (2014) 94: 355–82. doi: 10.1152/physrev.00030.2013

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

2. Vaitkus JA, Farrar JS, Celi FS. Thyroid hormone mediated modulation of energy expenditure. *Int J Mol Sci.* (2015) 16: 16158–75. doi: 10.3390/ijms160716158

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

3. Flamant F, Cheng SY, Hollenberg AN, Moeller LC, Samarut J, Wondisford FE, et al. Thyroid hormone signaling pathways: time for a more precise nomenclature. *Endocrinology* (2017) 158: 2052–7. doi: 10.1210/en.2017-00250

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

4. Davis PJ, Goglia F, Leonard JL. Nongenomic actions of thyroid hormone. *Nat Rev Endocrinol.* (2016) 12: 111–21. doi: 10.1038/nrendo.2015.205

[CrossRef Full Text](#) | [Google Scholar](#)

5. Moreno M, de Lange P, Lombardi A, Silvestri E, Lanni A, Goglia F. Metabolic effects of thyroid hormone derivatives. *Thyroid* (2008) 18: 239–53. doi: 10.1089/thy.2007.0248

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

6. Senese R, Cioffi F, de Lange P, Goglia F, Lanni A. Thyroid: biological actions of ‘nonclassical’ thyroid hormones. *J Endocrinol.* (2014a) 221: R1–12. doi: 10.1530/JOE-13-0573

[PubMed Abstract](#) | [CrossRef Full Text](#)

7. Senese R, Lasala P, Leanza C, de Lange P. New avenues for regulation of lipid metabolism by thyroid hormones and analogs. *Front Physiol.* (2014b) 5: 475. doi: 10.3389/fphys.2014.00475

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

8. Gnocchi D, Steffensen KR, Bruscalupi G, Parini P. Emerging role of thyroid hormone metabolites. *Acta Physiol.* (2016) 217: 184–216. doi: 10.1111/apha.12648

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

9. Cioffi F, Senese R, Lanni A, Goglia F. Thyroid hormones and mitochondria: with a brief look at derivatives and analogues. *Mol Cell Endocrinol.* (2013) 379: 51–61. doi: 10.1016/j.mce.2013.06.006

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

10. Goglia F. The effects of 3, 5-diiodothyronine on energy balance. *Front Physiol.* (2014) 5: 528. doi: 10.3389/fphys.2014.00528

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

11. Lanni A, Moreno M, Goglia F. Mitochondrial actions of thyroid hormone. *Compr Physiol.* (2016) 6: 1591–607. doi: 10.1002/cphy.c150019

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

12. Horst C, Rokos H, Seitz HJ. Rapid stimulation of hepatic oxygen consumption by 3, 5-di-iodo-L-thyronine. *Biochem J.* (1989) 261: 945–50. doi: 10.1042/bj2610945

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

13. Lanni A, Moreno M, Cioffi M, Goglia F. Effect of 3, 3'-diiodothyronine and 3, 5-diiodothyronine on rat liver oxidative capacity. *Mol Cell Endocrinol.* (1992) 86: 143–8. doi: 10. 1016/0303-7207(92)90138-V

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

14. Lanni A, Moreno M, Cioffi M, Goglia F. Effect of 3, 3'-di-iodothyronine and 3, 5-di-iodothyronine on rat liver mitochondria. *J Endocrinol.* (1993) 136: 59–64. doi: 10. 1677/joe. 0. 1360059

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

15. O'Reilly I, Murphy MP. Studies on the rapid stimulation of mitochondrial respiration by thyroid hormones. *Acta Endocrinol.* (1992) 127: 542–6. doi: 10. 1530/acta. 0. 1270542

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

16. Lanni A, Moreno M, Lombardi A, Goglia F. Calorigenic effect of diiodothyronines in the rat. *J Physiol.* (1996) 494 (Pt 3), 831–7. doi: 10. 1113/jphysiol. 1996. sp021536

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

17. Moreno M, Lanni A, Lombardi A, Goglia F. How the thyroid controls metabolism in the rat: different roles for triiodothyronine and diiodothyronines. *J Physiol.* (1997) 505 (Pt 2): 529–38. doi: 10. 1111/j. 1469-7793. 1997. 529bb. x

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

<https://assignbuster.com/35-diiodothyronine-a-novel-thyroid-hormone-metabolite-and-potent-modulator-of-energy-metabolism/>

18. Tata JR. Inhibition of the biological action of thyroid hormones by Actinomycin D and puromycin. *Nature* (1963) 197: 1167–8. doi: 10.1038/1971167a0

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

19. Mendoza A, Navarrete-Ramirez P, Hernandez-Puga G, Villalobos P, Holzer G, Renaud JP, et al. 3, 5-T₂ is an alternative ligand for the thyroid hormone receptor beta1. *Endocrinology* (2013) 154: 2948–58. doi: 10.1210/en.2013-1030

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

20. Moreno M, Lombardi A, Beneduce L, Silvestri E, Pinna G, Goglia F, et al. Are the effects of T₃ on resting metabolic rate in euthyroid rats entirely caused by T₃ itself? *Endocrinology* (2002) 143: 504–10. doi: 10.1210/endo.143.2.8613

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

21. Lanni A, Moreno M, Horst C, Lombardi A, Goglia F. Specific binding sites for 3, 3'-diiodo-L-thyronine (3, 3'-T₂) in rat liver mitochondria. *FEBS Lett.* (1994) 351: 237–40. doi: 10.1016/0014-5793(94)00840-X

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

22. Goglia F, Lanni A, Barth J, Kadenbach B. Interaction of diiodothyronines with isolated cytochrome c oxidase. *FEBS Lett.* (1994) 346: 295–8. doi: 10.1016/0014-5793(94)00476-5

<https://assignbuster.com/35-diiodothyronine-a-novel-thyroid-hormone-metabolite-and-potent-modulator-of-energy-metabolism/>

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

23. Arnold S, Goglia F, Kadenbach B. 3, 5-diiodothyronine binds to subunit Va of cytochrome-c oxidase and abolishes the allosteric inhibition of respiration by ATP. *Eur J Biochem.* (1998) 252: 325–30. doi: 10. 1046/j. 1432-1327. 1998. 2520325. x

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

24. Kadenbach B, Huttemann M, Arnold S, Lee I, Bender E. Mitochondrial energy metabolism is regulated via nuclear-coded subunits of cytochrome c oxidase. *Free Radic Biol Med.* (2000) 29: 211–21. doi: 10. 1016/S0891-5849(00)00305-1

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

25. Moreno M, Silvestri E, Lombardi A, Visser TJ, Goglia F, Lanni A. Identification of 3, 5-diiodo-L-thyronine-binding proteins in rat liver cytosol by photoaffinity labeling. *Endocrinology* (2003) 144: 2297–303. doi: 10. 1210/en. 2002-0174

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

26. Incerpi S, De Vito P, Luly P, Spagnuolo S, Leoni S. Short-term effects of thyroid hormones and 3, 5-diiodothyronine on membrane transport systems in chick embryo hepatocytes. *Endocrinology* (2002) 143: 1660–8. doi: 10. 1210/endo. 143. 5. 8767

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

<https://assignbuster.com/35-diiodothyronine-a-novel-thyroid-hormone-metabolite-and-potent-modulator-of-energy-metabolism/>

27. Alisi A, Spagnuolo S, Napoletano S, Spaziani A, Leoni S. Thyroid hormones regulate DNA-synthesis and cell-cycle proteins by activation of PKC α and p42/44 MAPK in chick embryo hepatocytes. *J Cell Physiol.* (2004) 201: 259–65. doi: 10. 1002/jcp. 20060

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

28. Incerpi S, Scapin S, D'Arezzo S, Spagnuolo S, Leoni S. Short-term effects of thyroid hormone in prenatal development and cell differentiation. *Steroids* (2005) 70: 434–43. doi: 10. 1016/j. steroids. 2005. 02. 009

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

29. Scapin S, Leoni S, Spagnuolo S, Fiore AM, Incerpi S. Short-term effects of thyroid hormones on Na⁺-K⁺-ATPase activity of chick embryo hepatocytes during development: focus on signal transduction. *Am J Physiol Cell Physiol.* (2009) 296: C4–12. doi: 10. 1152/ajpcell. 90604. 2007

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

30. Kadenbach B. Intrinsic and extrinsic uncoupling of oxidative phosphorylation. *Biochim Biophys Acta* (2003) 1604: 77–94. doi: 10. 1016/S0005-2728(03)00027-6

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

31. Lombardi A, Lanni A, Moreno M, Brand MD, Goglia F. Effect of 3, 5-di-iodo-L-thyronine on the mitochondrial energy-transduction apparatus. *Biochem J.* (1998) 330 (Pt 1): 521–6. doi: 10. 1042/bj3300521

<https://assignbuster.com/35-diiodothyronine-a-novel-thyroid-hormone-metabolite-and-potent-modulator-of-energy-metabolism/>

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

32. Lombardi A, Lanni A, de Lange P, Silvestri E, Grasso P, Senese R, et al. Acute administration of 3, 5-diiodo-L-thyronine to hypothyroid rats affects bioenergetic parameters in rat skeletal muscle mitochondria. *FEBS Lett.* (2007) 581: 5911–6. doi: 10. 1016/j. febslet. 2007. 11. 073

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

33. Lombardi A, de Lange P, Silvestri E, Busiello RA, Lanni A, Goglia F, et al. 3, 5-Diiodo-L-thyronine rapidly enhances mitochondrial fatty acid oxidation rate and thermogenesis in rat skeletal muscle: AMP-activated protein kinase involvement. *Am J Physiol Endocrinol Metab.* (2009) 296: E497–502. doi: 10. 1152/ajpendo. 90642. 2008

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

34. Hummerich H, Soboll S. Rapid stimulation of calcium uptake into rat liver by L-tri-iodothyronine. *Biochem J.* (1989) 258: 363–7. doi: 10. 1042/bj2580363

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

35. Del Viscovo A, Secondo A, Esposito A, Goglia F, Moreno M, Canzoniero LM. Intracellular and plasma membrane-initiated pathways involved in the $[Ca^{2+}]_i$ elevations induced by iodothyronines (T3 and T2) in pituitary GH3 cells. *Am J Physiol Endocrinol Metab.* (2012) 302: E1419–30. doi: 10. 1152/ajpendo. 00389. 2011

<https://assignbuster.com/35-diiodothyronine-a-novel-thyroid-hormone-metabolite-and-potent-modulator-of-energy-metabolism/>

[CrossRef Full Text](#)

36. Cavallo A, Gnoni A, Conte E, Siculella L, Zanotti F, Papa S, et al. 3, 5-diiodo-L-thyronine increases FoF1-ATP synthase activity and cardiolipin level in liver mitochondria of hypothyroid rats. *J Bioenerg Biomembr.* (2011) 43: 349–57. doi: 10. 1007/s10863-011-9366-3

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

37. Cavallo A, Taurino F, Damiano F, Siculella L, Sardanelli AM, Gnoni A. Acute administration of 3, 5-diiodo-L-thyronine to hypothyroid rats stimulates bioenergetic parameters in liver mitochondria. *J Bioenerg Biomembr.* (2016) 48: 521–9. doi: 10. 1007/s10863-016-9686-4

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

38. Lanni A, Moreno M, Lombardi A, Goglia F. 3, 5-Diiodo-L-thyronine and 3, 5, 3'-triiodo-L-thyronine both improve the cold tolerance of hypothyroid rats, but possibly via different mechanisms. *Pflugers Arch* (1998) 436: 407–14. doi: 10. 1007/s004240050650

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

39. Cimmino M, Mion F, Goglia F, Minaire Y, Geloen A. Demonstration of *in vivo* metabolic effects of 3, 5-di-iodothyronine. *J Endocrinol.* (1996)149: 319–25. doi: 10. 1677/joe. 0. 1490319

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

40. Mangiullo R, Gnoni A, Damiano F, Siculella L, Zanotti F, Papa S, et al. 3, 5-diiodo-L-thyronine upregulates rat-liver mitochondrial F(o)F(1)-ATP synthase by GA-binding protein/nuclear respiratory factor-2. *Biochim Biophys Acta* (2010) 1797: 233–40. doi: 10. 1016/j. bbabio. 2009. 10. 009

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

41. Lombardi A, De Matteis R, Moreno M, Napolitano L, Busiello RA, Senese R, et al. Responses of skeletal muscle lipid metabolism in rat gastrocnemius to hypothyroidism and iodothyronine administration: a putative role for FAT/CD36. *Am J Physiol Endocrinol Metab.* (2012) 303: E1222–33. doi: 10. 1152/ajpendo. 00037. 2012

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

42. Lombardi A, Senese R, De Matteis R, Busiello RA, Cioffi F, Goglia F, et al. 3, 5-Diiodo-L-thyronine activates brown adipose tissue thermogenesis in hypothyroid rats. *PLoS ONE* (2015) 10: e0116498. doi: 10. 1371/journal. pone. 0116498

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

43. Grasselli E, Voci A, Canesi L, De Matteis R, Goglia F, Cioffi F, et al. Direct effects of iodothyronines on excess fat storage in rat hepatocytes. *J Hepatol.* (2011a) 54: 1230–6. doi: 10. 1016/j. jhep. 2010. 09. 027

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

44. Grasselli E, Voci A, Demori I, Vecchione G, Compalati AD, Gallo G, et al. Triglyceride mobilization from lipid droplets sustains the anti-steatotic action of iodothyronines in cultured rat hepatocytes. *Front Physiol.* (2015) 6: 418. doi: 10.3389/fphys.2015.00418

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

45. Gnocchi D, Massimi M, Alisi A, Incerpi S, Bruscalupi G. Effect of fructose and 3, 5-diiodothyronine (3, 5-T(2)) on lipid accumulation and insulin signalling in non-alcoholic fatty liver disease (NAFLD)-like rat primary hepatocytes. *Horm Metab Res.* (2014) 46: 333–40. doi: 10.1055/s-0034-1371858

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

46. Fallahi P, Ferrari SM, Santini E, Camastra S, Frenzilli G, Puccini M, et al. Both 3, 5-diiodo-L-thyronine (T2) and T3 modulate glucose-induced insulin secretion. *J Biol Regul Homeost Agents* (2017) 31: 503–8.

[PubMed Abstract](#) | [Google Scholar](#)

47. Grasselli E, Voci A, Canesi L, Goglia F, Ravera S, Panfoli I, et al. Non-receptor-mediated actions are responsible for the lipid-lowering effects of iodothyronines in FaO rat hepatoma cells. *J Endocrinol.* (2011b) 210: 59–69. doi: 10.1530/JOE-11-0074

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

48. Rochira A, Damiano F, Marsigliante S, Gnoni GV, Siculella L. 3, 5-Diiodo-L-thyronine induces SREBP-1 proteolytic cleavage block and apoptosis in human hepatoma (Hepg2) cells. *Biochim Biophys Acta* (2013) 1831: 1679–89. doi: 10. 1016/j. bbalip. 2013. 08. 003

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

49. Coppola M, Glinni D, Moreno M, Cioffi F, Silvestri E, Goglia F. Thyroid hormone analogues and derivatives: actions in fatty liver. *World J Hepatol.* (2014) 6: 114–29. doi: 10. 4254/wjh. v6. i3. 114

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

50. Lanni A, Moreno M, Lombardi A, de Lange P, Silvestri E, Ragni M, et al. 3, 5-diiodo-L-thyronine powerfully reduces adiposity in rats by increasing the burning of fats. *FASEB J.* (2005) 19: 1552–4. doi: 10. 1096/fj. 05-3977fje

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

51. de Lange P, Cioffi F, Senese R, Moreno M, Lombardi A, Silvestri E, et al. Nonthyrotoxic prevention of diet-induced insulin resistance by 3, 5-diiodo-L-thyronine in rats. *Diabetes* (2011) 60: 2730–9. doi: 10. 2337/db11-0207

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

52. Senese R, Cioffi F, de Lange P, Leanza C, Iannucci LF, Silvestri E, et al. Both 3, 5-diiodo-L-thyronine and 3, 5, 3'-triiodo-L-thyronine prevent short-term hepatic lipid accumulation via distinct mechanisms in rats being fed a high-fat diet. *Front Physiol.* (2017) 8: 706. doi: 10. 3389/fphys. 2017. 00706

<https://assignbuster.com/35-diiodothyronine-a-novel-thyroid-hormone-metabolite-and-potent-modulator-of-energy-metabolism/>

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

53. Iannucci LF, Cioffi F, Senese R, Goglia F, Lanni A, Yen PM, et al. Metabolomic analysis shows differential hepatic effects of T2 and T3 in rats after short-term feeding with high fat diet. *Sci Rep.* (2017) 7: 2023. doi: 10.1038/s41598-017-02205-1

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

54. Moreno M, Silvestri E, De Matteis R, de Lange P, Lombardi A, Glinni D, et al. 3, 5-Diiodo-L-thyronine prevents high-fat-diet-induced insulin resistance in rat skeletal muscle through metabolic and structural adaptations. *FASEB J.* (2011) 25: 3312–24. doi: 10.1096/fj.11-181982

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

55. Zhang Y, Ye J. Mitochondrial inhibitor as a new class of insulin sensitizer. *Acta Pharm Sin B* (2012) 2: 341–9. doi: 10.1016/j.apsb.2012.06.010

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

56. Holloszy JO. “ Deficiency” of mitochondria in muscle does not cause insulin resistance. *Diabetes* (2013) 62: 1036–40. doi: 10.2337/db12-1107

[CrossRef Full Text](#) | [Google Scholar](#)

57. Meng ZX, Li S, Wang L, Ko HJ, Lee Y, Jung DY, et al. Baf60c drives glycolytic metabolism in the muscle and improves systemic glucose homeostasis through Deptor-mediated Akt activation. *Nat Med.* (2013) 19: 640–5. doi: 10.1038/nm.3144

<https://assignbuster.com/35-diiodothyronine-a-novel-thyroid-hormone-metabolite-and-potent-modulator-of-energy-metabolism/>

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

58. Jaspers RT, Zillikens MC, Friesema EC, delli Paoli G, Bloch W, Uitterlinden AG, et al. Exercise, fasting, and mimetics: toward beneficial combinations? *FASEB J.* (2017) 31: 14–28. doi: 10. 1096/fj. 201600652R

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

59. Silvestri E, Cioffi F, De Matteis R, Senese R, de Lange P, Coppola M, et al. 3, 5-Diiodo-L-thyronine affects structural and metabolic features of skeletal muscle mitochondria in high-fat-diet fed rats producing a co-adaptation to the glycolytic fiber phenotype. *Front Physiol.* (2018) 9: 194. doi: 10. 3389/fphys. 2018. 00194

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

60. Shang G, Gao P, Zhao Z, Chen Q, Jiang T, Zhang N, et al. 3, 5-Diiodo-L-thyronine ameliorates diabetic nephropathy in streptozotocin-induced diabetic rats. *Biochim Biophys Acta* (2013) 1832: 674–84. doi: 10. 1016/j. bbadis. 2013. 01. 023

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

61. Ball SG, Sokolov J, Chin WW. 3, 5-Diiodo-L-thyronine (T2) has selective thyromimetic effects *in vivo* and *in vitro* . *J Mol Endocrinol.* (1997) 19: 137–47. doi: 10. 1677/jme. 0. 0190137

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

62. Mollica MP, Lionetti L, Moreno M, Lombardi A, De Lange P, Antonelli A, et al. 3, 5-diiodo-L-thyronine, by modulating mitochondrial functions, reverses hepatic fat accumulation in rats fed a high-fat diet. *J Hepatol.* (2009) 51: 363–70. doi: 10. 1016/j. jhep. 2009. 03. 023

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

63. Silvestri E, Cioffi F, Glinni D, Ceccarelli M, Lombardi A, de Lange P, et al. Pathways affected by 3, 5-diiodo-L-thyronine in liver of high fat-fed rats: evidence from two-dimensional electrophoresis, blue-native PAGE, and mass spectrometry. *Mol Biosyst.* (2010) 6: 2256–71. doi: 10. 1039/c0mb00040j

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

64. Padron AS, Neto RA, Pantaleao TU, de Souza dos Santos MC, Araujo RL, de Andrade BM, et al. Administration of 3, 5-diiodothyronine (3, 5-T₂) causes central hypothyroidism and stimulates thyroid-sensitive tissues. *J Endocrinol.* (2014) 221: 415–27. doi: 10. 1530/JOE-13-0502

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

65. Vatner DF, Snikeris J, Popov V, Perry RJ, Rahimi Y, Samuel VT. 3, 5 Diiodo-L-Thyronine (T₂) does not prevent hepatic steatosis or insulin resistance in fat-fed sprague dawley rats. *PLoS ONE* (2015) 10: e0140837. doi: 10. 1371/journal. pone. 0140837

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

66. Galan X, Llobera M, Ramirez I. Lipoprotein lipase and hepatic lipase in wistar and sprague-dawley rat tissues. Differences in the effects of gender and fasting . *Lipids* (1994) 29: 333-6. doi: 10. 1007/BF02537186

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

67. Jonas W, Lietzow J, Wohlgemuth F, Hoefig CS, Wiedmer P, Schweizer U, et al. 3, 5-Diiodo-L-thyronine (3, 5-t₂) exerts thyromimetic effects on hypothalamus-pituitary-thyroid axis, body composition, and energy metabolism in male diet-induced obese mice. *Endocrinology* (2015) 156: 389-99. doi: 10. 1210/en. 2014-1604

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

68. Lietzow J, Golchert J, Homuth G, Volker U, Jonas W, Kohrle J. 3, 5-T₂ alters murine genes relevant for xenobiotic, steroid, and thyroid hormone metabolism. *J Mol Endocrinol.* (2016) 56: 311-23. doi: 10. 1530/JME-15-0159

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

69. Goldberg IJ, Huang LS, Huggins LA, Yu S, Nagareddy PR, Scanlan TS, et al. Thyroid hormone reduces cholesterol via a non-LDL receptor-mediated pathway. *Endocrinology* (2012) 153: 5143-9. doi: 10. 1210/en. 2012-1572

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

70. Moreno M, Silvestri E, Coppola M, Goldberg IJ, Huang LS, Salzano AM, et al. 3, 5, 3'-triiodo-L-thyronine- and 3, 5-diiodo-L-thyronine- affected metabolic

pathways in liver of LDL receptor deficient mice. *Front Physiol.* (2016) 7: 545. doi: 10.3389/fphys.2016.00545

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

71. da Silva Teixeira S, Filgueira C, Sieglaff DH, Benod C, Villagomez R, Minze LJ, et al. 3, 5-diiodothyronine (3, 5-T₂) reduces blood glucose independently of insulin sensitization in obese mice. *Acta Physiol.* (2017) 220: 238–50. doi: 10.1111/apha.12821

[CrossRef Full Text](#) | [Google Scholar](#)

72. Antonelli A, Fallahi P, Ferrari SM, Di Domenicantonio A, Moreno M, Lanni A, et al. 3, 5-diiodo-L-thyronine increases resting metabolic rate and reduces body weight without undesirable side effects. *J Biol Regul Homeost Agents* (2011) 25: 655–60.

[PubMed Abstract](#) | [Google Scholar](#)

73. Faber J, Kirkegaard C, Lumholtz IB, Siersbaek-Nielsen K, Friis T. Simultaneous measurement of 3, 5-diiodothyronine and 3, 5, 3'-triiodothyronine turnover kinetics in euthyroid hyperthyroid, and hypothyroid subjects. *J Clin Endocrinol Metab.* (1982) 55: 8–12. doi: 10.1210/jcem-55-1-8

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

74. Engler D, Merkelbach U, Steiger G, Burger AG. The monodeiodination of triiodothyronine and reverse triiodothyronine in man: a quantitative

evaluation of the pathway by the use of turnover rate techniques. *J Clin Endocrinol Metab.* (1984) 58: 49–61. doi: 10. 1210/jcem-58-1-49

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

75. Pinna G, Meinhold H, Hiedra L, Thoma R, Hoell T, Graf KJ, et al. Elevated 3, 5-diiodothyronine concentrations in the sera of patients with nonthyroidal illnesses and brain tumors. *J Clin Endocrinol Metab.* (1997) 82: 1535–42. doi: 10. 1210/jcem. 82. 5. 3939

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

76. Lehmpful I, Brabant G, Wallaschofski H, Ruchala M, Strasburger CJ, Kohrle J, et al. Detection of 3, 5-diiodothyronine in sera of patients with altered thyroid status using a new monoclonal antibody-based chemiluminescence immunoassay. *Thyroid* (2014) 24: 1350–60. doi: 10. 1089/thy. 2013. 0688

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

77. Pietzner M, Homuth G, Budde K, Lehmpful I, Volker U, Volzke H, et al. Urine metabolomics by (1)H-NMR spectroscopy indicates associations between serum 3, 5-T2 concentrations and intermediary metabolism in euthyroid humans. *Eur Thyroid J.* (2015a) 4(Suppl. 1): 92–100. doi: 10. 1159/000381308

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

78. Pietzner M, Lehmpful I, Friedrich N, Schurmann C, Ittermann T, Dorr M, et al. Translating pharmacological findings from hypothyroid rodents to euthyroid humans: is there a functional role of endogenous 3, 5-T₂? *Thyroid* (2015b) 25: 188–97. doi: 10. 1089/thy. 2014. 0262

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

79. Dietrich JW, Muller P, Schiedat F, Schlomicher M, Strauch J, Chatzitomaris A, et al. Nonthyroidal illness syndrome in cardiac illness involves elevated concentrations of 3, 5-diiodothyronine and correlates with atrial remodeling. *Eur Thyroid J.* (2015) 4: 129–37. doi: 10. 1159/000381543

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

80. Langouche L, Lehmpful I, Perre SV, Kohrle J, Van den Berghe G. Circulating 3-T₁AM and 3, 5-T₂ in critically ill patients: a cross-sectional observational study. *Thyroid* (2016) 26: 1674–80. doi: 10. 1089/thy. 2016. 0214

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

81. Leary SC, Barton KN, Ballantyne JS. Direct effects of 3, 5, 3'-triiodothyronine and 3, 5-diiodothyronine on mitochondrial metabolism in the goldfish *Carassius auratus*. *Gen Comp Endocrinol.* (1996) 104: 61–6. doi: 10. 1006/gcen. 1996. 0141

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

82. Garcia GC, Jeziorski MC, Valverde RC, Orozco A. Effects of iodothyronines on the hepatic outer-ring deiodinating pathway in killifish. *Gen Comp Endocrinol.* (2004) 135: 201–9. doi: 10. 1016/j. ygcen. 2003. 09. 010

[CrossRef Full Text](#) | [Google Scholar](#)

83. Little AG, Kunisue T, Kannan K, Seebacher F. Thyroid hormone actions are temperature-specific and regulate thermal acclimation in zebrafish (*Danio rerio*). *BMC Biol.* (2013) 11: 26. doi: 10. 1186/1741-7007-11-26

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

84. Navarrete-Ramirez P, Luna M, Valverde RC, Orozco A. 3, 5-di-iodothyronine stimulates tilapia growth through an alternate isoform of thyroid hormone receptor beta1. *J Mol Endocrinol.* (2014) 52: 1–9. doi: 10. 1530/JME-13-0145

[PubMed Abstract](#) | [CrossRef Full Text](#)

85. Hernandez-Puga G, Navarrete-Ramirez P, Mendoza A, Olvera A, Villalobos P, Orozco A. 3, 5-Diiodothyronine-mediated transrepression of the thyroid hormone receptor beta gene in tilapia. Insights on cross-talk between the thyroid hormone and cortisol signaling pathways . *Mol Cell Endocrinol.* (2016) 425: 103–10. doi: 10. 1016/j. mce. 2016. 01. 023

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)

86. Olvera A, Martyniuk CJ, Buisine N, Jimenez-Jacinto V, Sanchez-Flores A, Sachs LM, et al. Differential transcriptome regulation by 3, 5-T₂ and 3', 3, 5-

<https://assignbuster.com/35-diiodothyronine-a-novel-thyroid-hormone-metabolite-and-potent-modulator-of-energy-metabolism/>

T3 in brain and liver uncovers novel roles for thyroid hormones in tilapia. *Sci Rep.* (2017) 7: 15043. doi: 10. 1038/s41598-017-14913-9

[PubMed Abstract](#) | [CrossRef Full Text](#) | [Google Scholar](#)